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The occurrence and extent of apoptosis in the kidneys of
patients with diabetic nephropathy is largely unknown. We
evaluated apoptosis in renal biopsies obtained from patients
with early or advanced type II diabetic nephropathy.
Apoptosis was about 6- and 3-fold higher, respectively, in
glomeruli and tubules in kidneys of patients with early
nephropathy than in the normal kidney and this was not
further increased in advanced diabetic nephropathy.
Glomerular apoptosis was related directly to hemoglobin A1c
and systolic blood pressure, whereas tubular cell apoptosis
correlated to diabetes duration and low-density lipoprotein-
cholesterol. Fas, Fas ligand, and p38 mitogen-activated
protein kinase expressions were enhanced in glomeruli and
tubules; however, this did not correlate with apoptosis. In
patients with proteinuria, apoptosis was associated with the
subsequent loss of kidney function. When these parameters
were subjected to multivariate analysis, only glomerular
apoptosis retained a significant independent predictive
value. Our findings suggest that apoptosis might be a
clinically relevant mechanism of glomerular and tubular cell
loss in proteinuric type II diabetic patients.
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The nephropathy of type II diabetes mellitus is the main
cause of end-stage renal disease in developed countries.1
Renal lesions in the nephropathy of type II diabetes reflect
several patterns of renal injury, owing to diabetes ‘per se,’
nephroangiosclerosis, or non-diabetic kidney diseases.2,3
Hyperglycemia generates a cascade of events in the kidney,
which finally result in mesangial extracellular matrix
accumulation.4 These include the production of proinflam-
matory cytokines and growth factors with abnormal vascular
permeability, formation of advanced glycation end products,
and increased oxidative stress.5–9 Clinical studies in patients
with type II diabetic nephropathy also report a loss of
glomerular cells that correlates with the progression to
diabetic glomerulosclerosis.10,11 However, most of these
studies have examined the advanced stages of diabetic disease
and did not address the mechanisms of glomerular cell death.
Apoptosis, a mode of cell death which is mediated by the
activation of the caspases and results in the cleavage of
protein substrates and DNA fragmentation, has been
proposed to cause loss of kidney cells in diabetic kidney
disease. Apoptosis of kidney podocytes, epithelial cells, and
tubular cells has been demonstrated in cell cultures under the
expression of glucose-induced apoptotic signals.5–9 Hyper-
glycemia has also been shown to induce in vitro apoptosis of
several other non-kidney cells.12–15 In addition to hyper-
glycemia, physical stretch induced by hypertension,16 dysre-
gulation of the Fas/Fas ligand (FasL) system,15–17 and of
mitogen-activated protein (MAP) kinase (p38 MAPK)
intracellular signaling18–20 have been suggested to favor
apoptotic cell loss in diabetes.
In spite of our increased understanding of mechanisms
potentially involved in apoptotic cell loss in diabetes, how
and to what extent apoptotic changes are observed during the
course of type II diabetic nephropathy has been scarcely
studied. In addition, predictors of apoptosis in diabetic
nephropathy have not been described. In this study we
examined the occurrence of apoptosis in renal biopsies from
type II diabetic patients at different clinical stages, from
proteinuria to moderate-advanced diabetic chronic kidney
disease. As both metabolic and hemodynamic factors have
been implicated in the pathogenesis of diabetic nephro-
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2007 International Society of Nephrology
Received 31 January 2007; revised 5 July 2007; accepted 10 July 2007;
published online 12 September 2007
Correspondence: G Garibotto, Nephrology Division, Department of Internal
Medicine, Genoa University, Viale Benedetto XV, 6, Genoa 16132, Italy.
E-mail: gari@unige.it
1262 Kidney International (2007) 72, 1262–1272
pathy,1,4,21 we also examined the role of different clinical and
biochemical parameters as potential predictors of kidney
apoptotic changes.
RESULTS
Apoptotic changes are enhanced in the kidney of patients
with type II diabetic nephropathy
In this study apoptosis was detected by an assay, which is
based on monoclonal antibodies to single-stranded DNA
(ssDNA).22 This technique appears to be more accurate than
the previously employed terminal deoxynucleotidyl transfer-
ase-mediated dUTP nick-end labeling (TUNEL), since
TUNEL also detects necrotic and autolytic types of cell
death.22 In addition, the sensitivity of TUNEL appears to be
low in the detection of early apoptotic changes as compared
to the anti-ssDNA used in this study, since it detects late
stages of apoptosis associated with the low-molecular-weight
DNA fragmentation.22,23
The number of cells with anti-ssDNA-positive signal was
significantly higher in the kidney of patients with diabetic
nephropathy than in controls and in patients with glomer-
ulonephritis (Figures 1 and 2). The anti-ssDNA signal was
not only confined to glomerular and tubular cells, but it was
also detected in vascular endothelial cells. Apoptosis was
increased by B6- and B3-folds, respectively, in the
glomeruli (3.070.6%) and tubuli (0.8970.2%) (Po0.05 vs
controls) and was not different in patients with early or
advanced disease. Proliferating cell nuclear antigen, a marker
of cell proliferation, was similar in patients and controls.
Apoptosis tended to be related directly to proliferation both
in glomeruli (r¼ 0.40; Po0.055) and tubuli (r¼ 0.41;
Po0.055). As a consequence of these changes, the ratio
proliferation/apoptosis was markedly reduced in diabetic
patients vs controls both in glomeruli and tubuli (Figure 3).
Tubular apoptosis was related to the duration of diabetes
(r¼ 0.82; Po0.006) and low-density lipoprotein (LDL)-
cholesterol (r¼ 0.63; Po0.04), whereas no correlation was
found between glomerular apoptosis and other clinical
parameters in proteinuric patients. When all patients with
diabetic nephropathy were considered, glomerular apoptosis
was related directly to HbA1c levels and systolic blood
pressure (Table 1, and Figures 4 and 5). Tubular apoptosis
was related to the duration of diabetes and LDL-cholesterol
levels (Table 1 and Figure 6). When these parameters were
multivariately analyzed, only systolic pressure (Po0.02) for
the glomerular compartment and LDL-cholesterol (Po0.01)
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Figure 1 | Glomerular and tubular apoptosis by ssDNA antibodies analysis. Serial sections of kidneys with type II diabetic nephropathy
were stained for apoptosis using the ssDNA Ab. Black arrows point to cells that display the nuclear fragmentation and condensation
characteristic of apoptosis. The anti-ssDNA signal was not only confined to glomerular cells (a and b, mesangial cells; c, podocytes;
d, endothelial cells), but it was also detected (e, f) in tubular and (g, h) vascular endothelial cells (original magnification  1000).
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Figure 2 | Apoptosis in the kidneys of patients with type II
diabetic nephropathy. (a) Patients with type II diabetic nephropathy
(DN) presented an increase in apoptotic index both in the glomeruli
and tubuli when compared to controls and patients affected by
nondiabetic nephropathies (GN). (b) Apoptosis was similarly
enhanced both in patients with early and in those with advanced
clinical impairment. aPo0.05; bPo0.01 vs controls and patients with
GN and proteinuria. Mean7s.e.m.
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and diabetes age (Po0.04) for the tubuli, retained a
significant predictive value.
When we compared the results of TUNEL and anti-
ssDNA, the percentage of apoptotic cells was extremely low in
normal glomeruli and tubuli (glomerular apoptosis:
0.3270.1% by TUNEL analysis and 0.3770.1% by anti-
ssDNA assay, P¼NS; tubular apoptosis: 0.1670.1% by
TUNEL analysis and 0.5170.2% by anti-ssDNA assay,
P¼NS). However, the number of cells with TUNEL-positive
signal was increasedB3- to 4-fold (Po0.05–0.02) vs controls
in patients with diabetic nephropathy (glomeruli: 1.070.2%,
tubuli: 0.6270.2%). Apoptosis detected by TUNEL was
directly correlated with apoptosis detected by anti-ssDNA
both in glomerular (r¼ 0.67; Po0.02) and tubular (r¼ 0.62;
Po0.05) compartments. Therefore, the increase in apoptotic
changes observed in patients with type II diabetic nephro-
pathy was qualitatively evident by both techniques.
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Figure 3 | Cell fate in type II diabetic nephropathy. Apoptosis and proliferation were quantified in the glomeruli and tubules in kidney
biopsies from patients with type II DN. In these patients, the proliferation/apoptosis ratio was markedly decreased in favor of apoptosis both in
glomeruli and tubuli. aPo0.05; bPo0.01 vs controls. Mean7s.e.m.
Table 1 | Univariate analysis of the correlation between some
clinical parameters and glomerular and tubule apoptosis in
patients with type II diabetic nephropathy (n=24)
Glomerular
apoptosis
Tubule cell
apoptosis
Clinical characteristics r P r P
Age (years) 0.14 NS 0.15 NS
Duration of diabetes (years) 0.23 NS 0.48 o0.05
Estimated GFR (ml/min per 1.73 m2) 0.30 NS 0.05 NS
BMI (kg/m2) 0.1 NS 0.1 NS
Proteinuria (g/day) 0.24 NS 0.25 NS
LDL-cholesterol (mg/dl) 0.22 NS 0.57 o0.01
HDL-cholesterol (mg/dl) 0.01 NS 0.07 NS
Triglycerides (mg/dl) 0.35 NS 0.30 NS
Blood glucose (mg/dl) 0.06 NS 0.03 NS
HbA1c (%) 0.44 o0.05 0.37 NS
Albuminemia (g/dl) 0.18 NS 0.04 NS
SBP (mm Hg) 0.45 o0.03 0.27 NS
DBP (mm Hg) 0.230 NS 0.03 NS
BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant;
SBP, systolic blood pressure.
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Figure 4 | Apoptosis in the kidneys of patients with type II
diabetic nephropathy. Apoptosis was directly associated with
HbA1c levels in the (a) glomeruli but not in (b) tubule cells in patients
with type II diabetic nephropathy.
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Glomerular and tubular Fas/FasL expressions are
upregulated in patients with type II diabetic nephropathy
Fas, a 45-kDa member of the tumor necrosis factor receptor
superfamily, binds to its cognate ligand, FasL, causing rapid
cell death.15,17 Fas and FasL protein expressions were present
in the normal kidney at minimal levels. Conversely, the
expression of both was markedly increased both in glomeruli
and tubuli (Figures 7–9). Table 2 shows the univariate
analysis of Fas/FasL expression and apoptosis, together with
several clinical parameters. Despite enhanced expression, Fas
and FasL did not correlate with apoptosis neither in tubules
nor in glomeruli. Although no clinical association was found
for enhanced Fas, FasL expression was related directly to age
(glomeruli and tubuli), proteinuria (glomeruli and tubuli),
estimated glomerular filtration rate (GFR; glomeruli), and
duration of diabetes (tubuli) (Po0.05–0.01).
Histological associations
No significant relation was observed between individual
structural kidney changes and apoptosis in the glomeruli and
tubuli in patients with proteinuria. When patients with
advanced diabetic disease were considered (Table 3), glo-
merular apoptosis was related directly to the histological
scores of glomerular sclerosis, mesangial proliferation, and
tubule atrophy. Tubular apoptosis was correlated with
glomerular sclerosis and tubular atrophy, but not with other
tubulo-interstitial score of damage.
No associations between glomerular Fas and structural
changes were found. Tubular Fas was related directly to
glomerular sclerosis and arterial hyalinosis. Glomerular FasL
was directly associated with interstitial fibrosis, tubule
atrophy, and with the global histologic score, whereas no
association was found between tubular FasL and structural
tubular changes (Table 3).
The expression of phosphorylated p38 MAPK is enhanced
in the kidney of patients with type II diabetic nephropathy
Minimal p38 activity was observed in glomeruli and tubuli
from normal kidneys (Figure 10). Conversely, the phos-
phorylated p38 MAPK was diffusely upregulated in glomeruli,
tubuli, and vessel endothelia in patients with early clinical
disease, and was not further expressed in patients with
advanced disease.
Glomerular, but not tubular, apoptosis is an early marker
of progression in patients with early clinical disease
During the 24-month follow-up period, estimated GFR
declined by B15 ml/min per 1.73 m2 in patients with
proteinuria. This average value is in the range of those
reported in proteinuric type II diabetic patients during a
similar time period.21,24 Of note, the apoptotic indexes both
in the glomerular and tubular compartments, as well as the
histologic global score, were associated with the rate of
subsequent kidney function loss (Table 4 and Figure 11).
However, when these parameters were multivariately ana-
lyzed in combination with proteinuria, histological global
score and estimated GFR, only the score of baseline
glomerular apoptosis and, at least in part, the estimated
GFR retained a significant independent predictive value
(Table 4). Thus, the degree of glomerular apoptosis, more
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Figure 5 | Apoptosis in the kidneys of patients with type II
diabetic nephropathy. Apoptosis was directly associated with
systolic blood pressure in the (a) glomeruli but not in (b) tubule cells
in patients with type II diabetic nephropathy.
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Figure 6 | Apoptosis in the kidneys of patients with type II
diabetic nephropathy. Apoptosis was associated with plasma
LDL-cholesterol in (b) tubule but not in (a) glomerular cells in
patients with type II diabetic nephropathy.
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than tubular apoptosis, may represent an early marker for
progression in type II diabetic nephropathy.
DISCUSSION
In this study, we tested the hypothesis that the acceleration of
apoptotic processes represents a clinically relevant mecha-
nism by which kidney cells are injured in type II diabetic
nephropathy. With this in mind, we used different assays for
the study of apoptosis and apoptosis effectors in kidney
biopsies of patients with type II diabetic nephropathy at
different clinical stages and examined the association of
several different parameters as potential predictors of kidney
apoptotic changes.
We found that apoptotic changes are diffusely increased
and observed in glomeruli, tubuli, and vascular endothelia in
patients with type II diabetic nephropathy. The proliferation/
apoptosis ratio was decreased in favor of apoptosis both in
glomeruli and tubuli, indicating that diabetic nephropathy is
a condition during which the balance of cell fate is pushed
toward apoptosis. According to our findings, apoptotic cell
loss is already observed in proteinuric patients with normal
or subnormal GFR and only modest chronic changes at the
time of their biopsy, suggesting that the acceleration of
apoptotic processes is an early phenomenon.
In epidemiological studies, higher baseline albuminuria,
hemoglobin A1c, and systolic blood pressure, together with
lower GFR, hemoglobin, and heavy smoking, were signifi-
cantly associated with more rapid progression of type II
diabetic kidney disease.24 In our study, some of these
identified predictors of progression were found also to be
associated with an enhancement of kidney apoptotic
processes. Significant associations were observed between
systolic blood pressure, together with HbA1c levels, and
apoptosis of glomerular cells, whereas tubule apoptosis was
best predicted by LDL levels and diabetes duration. The
association between the loss of glomerular cells and HbA1c
levels suggests a role of metabolic control on apoptotic
processes. This is in accordance to in vitro observations,7–9
showing a glucose-induced activation of apoptosis in several
kidney cell types. However, according to our findings, systolic
blood pressure is more strongly associated with glomerular
apoptosis than metabolic control. The mechanisms under-
lying this association are more than speculative. The
glomerulus in the diabetic kidney seems to be vulnerable,
particularly to the barotrauma caused by systemic arterial
hypertension.25,26 In addition, mechanical stretch, per se
or through Fas-dependent mechanism, promotes apoptosis
in vascular smooth muscle cells, mesangial cells, and
podocytes.27
In this study, apoptosis in the tubuli was accounted for by
diabetes age and LDL-cholesterol levels. High levels of plasma
lipids, particularly LDL and very LDL are among the
pathophysiologic stimuli that induce endothelial and
tubular cell apoptosis.28–32 In addition, albuminuria, as a
lipid carrier, can facilitate the proinflammatory activation of
proximal tubular cells30 and favor Fas-dependent apoptosis.31
Even if we could not find an association between proteinuria
and tubular apoptosis, we observed that proteinuria was
associated with FasL expression in kidney glomeruli and
tubuli.
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Figure 7 | Expression of Fas (immunohistochemistry) in (a–c) controls and in (d–f) kidney biopsies from patients with type II diabetic
nephropathy (c–f: original magnification  400; a, b: original magnification  1000). Results of image analysis are shown in g and h
(aPo0.05 vs controls). Fas expression was clearly upregulated both in glomeruli and tubuli. Mean7s.e.m.
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Figure 8 | Expression of FasL (immunohistochemistry and immunofluorescence) in (a, d) controls and in (b, c, e, f, h, i) patients with
type II diabetic nephropathy. FasL was upregulated both in the glomeruli and tubuli in patients with diabetic nephropathy. (j, k) Image
analysis (aPo0.05, bPo0.01 vs controls) (b, g, h: original magnification  400; a, d, f, i: original magnification  1000). Mean7s.e.m.
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An upregulation of Fas/FasL takes place in several cell
types in diabetes.15,17 A new finding reported here is that type
II diabetic kidney disease is associated with prominent kidney
Fas/FasL expression. Fas appears to be hyper-expressed both
in tubuli and in glomeruli (where it is directly associated with
glomerular sclerosis and arterial hyalinosis). Several factors
might explain these changes. Aging,32 hypertension, LDL-
cholesterol, and low-grade inflammation have been observed
to play a role in Fas-dependent cell death apoptosis in
experimental studies. In addition, Fas/FasL-mediated tubular
epithelial cell apoptosis has been suggested to be a feature of
chronic renal failure itself.33–37 As a matter of fact, our data
show that FasL expression in glomeruli, but not in tubuli,
increases progressively along with the decline in renal
function. However, the implications of the changes in the
Fas/FasL system are unclear, since no relationship was
observed between Fas/FasL expression and the anti-ssDNA
signal. Our data therefore suggest that other apoptotic
factor(s) are likely at play.
Hyperglycemia, osmotic stress, and proinflammatory
cytokines activate several MAPK signal transduction path-
ways18–20 and activated p38,38,39 leading to mechanisms
implicated in the pathogenesis of diabetic nephropathy. Our
data, indicating an enhanced expression on p38 MAPK in
patients with early clinical diabetic disease, are in accordance
with recent observations.18 It is of note that the activation of
this pathway has also been associated with protective
effects.20 Perhaps limited by the relatively low number of
cases available (n¼ 12), we could not find associations
between glomerular and tubular p38 MAPK and apoptosis.
Contrarywise, the expression of p38 MAPK in the glomeruli
was inversely associated with proteinuria (r¼0.69;
P¼ 0.036). This suggests that the phosphorylation of p38
MAPK represents an early adaptation to glycemic stress,
contributing to preservation of glomerular membrane base-
ment structures and albuminuria. Further studies are needed
to address this issue.
Loss of glomerular capillary cells is a feature of progressive
disease and has been found to correlate with glomerular
sclerosis, tubular damage, and rarefaction of peritubular
capillaries in the remnant kidney model.32 Although
apoptosis was already enhanced, no peculiar structural renal
lesion(s) were associated with glomerular or tubular
apoptotic changes in patients with proteinuria. In these
Table 2 | Univariate analysis of the correlation between apoptosis, clinical parameters, and glomerular and tubule Fas/FasL
expression in patients with type II diabetic nephropathy (n=24)
Glomeruli Tubuli
Fas FasL Fas FasL
Apoptosis and clinical characteristics r P r P r P r P
Apoptosis 0.03 NS 0.20 NS 0.24 NS 0.08 NS
Age (years) 0.06 NS 0.41 o0.05 0.31 NS 0.52 o0.01
Duration of diabetes (years) 0.38 NS 0.20 NS 0.13 NS 0.52 o0.01
Estimated GFR (ml/min per 1.73 m2) 0.05 NS 0.53 o0.01 0.25 NS 0.001 NS
BMI (kg/m2) 0.08 NS 0.01 NS 0.01 NS 0.35 NS
Proteinuria (g/day) 0.04 NS 0.41 o0.05 0.07 NS 0.44 o0.05
LDL-cholesterol (mg/dl) 0.17 NS 0.34 NS 0.001 NS 0.01 NS
HDL-cholesterol (mg/dl) 0.08 NS 0.23 NS 0.012 NS 0.01 NS
Triglycerides (mg/dl) 0.04 NS 0.35 NS 0.39 NS 0.37 NS
Blood glucose (mg/dl) 0.10 NS 0.18 NS 0.26 NS 0.24 NS
HbA1c (%) 0.30 NS 0.35 NS 0.12 NS 0.12 NS
Serum albumin (g/dl) 0.26 NS 0.1 NS 0.23 NS 0.23 NS
SBP (mm Hg) 0.22 NS 0.34 NS 0.39 NS 0.39 NS
DBP (mm Hg) 0.24 NS 0.14 NS 0.04 NS 0.04 NS
BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant; SBP,
systolic blood pressure.
Table 3 | Associations between structural changes, apoptosis, and apoptosis effectors in patients with type II diabetic
nephropathy (n=24)
Structural change Glomerular apoptosis Glomerular Fas Glomerular FasL Tubule apoptosis Tubular Fas Tubular FasL
Glomerular sclerosis r=0.428; Po0.05 NS NS r=0.41; Po0.05 r=0.57; Po0.01 NS
Percent sclerotic glomeruli NS NS NS NS NS NS
Mesangial proliferation r=0.62; Po0.002 NS NS NS NS NS
Glomerular ischemic lesions NS NS NS NS NS NS
Interstitial fibrosis r=0.48; Po0.05 NS r=0.51; Po0.02 NS NS NS
Interstitial inflammation NS NS NS NS NS NS
Tubular atrophy r=0.47; Po0.05 NS r=0.47; Po0.05 r=0.45; Po0.05 NS NS
Atherosclerosis NS NS NS NS NS NS
Arterial hyalinosis NS NS NS NS r=0.47; Po0.05 NS
Global score NS NS r=0.42; Po0.05 NS NS NS
NS, not significant.
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patients with normal or slightly decreased GFR, both
glomerular and tubular apoptosis predicted the loss of renal
function. Thus, the degree of apoptosis in patients with early
involvement of type II diabetic nephropathy may represent a
negative prognostic factor and a novel marker for progres-
sion. Proteinuria, total global histologic score, and baseline
GFR have been shown to predict the kidney survival in type
II diabetic nephropathy.2,24 However, at the earlier stages of
diabetic nephropathy, there are no light microscopy changes
that are predictive of the subsequent loss of renal function. In
this study, when both glomerular and tubular apoptosis were
included in a multiple regression analysis, only glomerular
apoptosis (and less consistently GFR) was found to predict
independently the loss of GFR. Thus, an elevated glomerular
cell apoptosis rate at the time of initial biopsy comes forth as
a novel and independent predictor of the loss of renal
function in our cohort of patients with early diabetic lesions.
These findings might be considered in view of the slow
turnover in capillary loop, as compared to the fast turnover
of tubules.40 This also suggests that there might be an
imbalance between cell injury and repair systems at least with
regard to the glomerular capillary tuft, and that this
imbalance becomes progressively more important along with
the progression of glomerular diabetic lesions.41
In conclusion, the results of this study demonstrate that
apoptosis of both glomerular and tubular cells is already
enhanced in patients with type II diabetic nephropathy
presenting proteinuria and nearly normal GFR, and that
acceleration of apoptotic processes in glomeruli and tubuli
likely contributes to decreased nephron remodeling. In
addition, this study provides a clinical basis for in vitro
studies of apoptosis regulatory molecules as a potential target
for therapeutic intervention in a common clinical condition
that is still associated with an unfavorable prognosis. With
this regard, the estimate of apoptosis in kidney biopsies could
also be considered a sensitive index of disease progression.
MATERIALS AND METHODS
Patients
Thirty-two patients with type II diabetes and proteinuria entered
into the study from the Department of Internal Medicine,
Nephrology Division, Genoa University. The inclusion and exclu-
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Figure 10 | Expression of phosphorylated p38 MAPK
(immunohistochemistry) in (a) controls (original magnification
 400) and in (b–d) patients with type II diabetic nephropathy
(original magnification  1000). Phosphorylated p38 was
upregulated in glomerular, tubular (aPo0.05 vs controls), and
vascular endothelial cells (a: original magnification  400;
b–d: original magnification  1000). Data7s.e.m.
Table 4 | Univariate and multivariate analysis of the
correlation between apoptosis, estimated proteinuria,
histologic global score, and loss of renal function at 2 years in
patients with type II diabetic nephropathy and early clinical
disease
Univariate
Multivariate
(model r2=0.83;
Po0.01)
Glomerular apoptosis 0.0035 0.0038
Tubule apoptosis 0.04 0.745
Proteinuria 0.41 0.722
Histologic global score 0.036 0.34
Estimated GFR 0.063 0.042
GFR, glomerular filtration rate.
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Figure 11 | Relationships between (a) glomerular and (b) tubule
cell apoptosis and loss of renal function at 2 years in patients
with type II diabetic nephropathy and proteinuria.
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sion criteria were defined to select a cohort of type II diabetic
patients whose proteinuria (4500 mg/24 h) was the result of
diabetic nephropathy. During admission, laboratory and clinical
data were collected and a percutaneous kidney biopsy was
performed. All subjects were informed about the nature, purposes,
procedures, and possible risks of the study before their informed
consent was obtained. The procedures were in accordance with the
Declaration of Helsinki Principle. The study was approved by the
Ethical Committee of the Department of Internal Medicine.
By renal biopsy examination, 24 patients were affected by
diabetic nephropathy. Eight patients were not considered for the
study because they were recognized to be affected by non-diabetic
(immunoglobulin A nephropathy, membranous, or membrano-
proliferative glomerulonephritis) renal disease. All kidney biopsy
specimens were analyzed by the same pathologist (Dr Ferrario). The
morphologic changes in kidney biopsies were considered for the
following categories: glomerular sclerosis (nodular or diffuse),
glomerular ischemic lesions, mesangial proliferation, interstitial
fibrosis, interstitial inflammation, tubular atrophy, atherosclerosis,
and arterial hyalinosis. Normal portions of kidney tissue from
nephrectomies for renal carcinoma (n¼ 8, six males and two
females, 6074 years) were examined as a control group. For
comparison, the kidney biopsy specimens of patients with
immunoglobulin A nephropathy (n¼ 6, five males and one females,
age 4677 years, estimated GFR 80720 ml/mn per 1.73 m2,
proteinuria 2.970.76 g/day) and membranous glomerulonephritis
(n¼ 6, four males and two females, age 4975 years, estimated GFR
105719 ml/min per 1.73 m2, proteinuria 3.270.6 g/day) were also
examined.
The clinical and laboratory characteristics of diabetic subjects are
summarized in Tables 5 and 6. Diabetic subjects were further
classified into two groups, based on urine protein excretion and
renal function. The first group of subjects had early clinical diabetic
nephropathy (defined by proteinuria 500–2000 mg/day and serum
creatinine p1.4 mg/dl). The second group of subjects had an
advanced clinical nephropathy (proteinuria 42000 mg/day and/or
serum creatinine 41.4 mg/dl). Systolic blood pressure was greater in
patients with more advanced disease. In this group of patients, also
the duration of diabetes and serum triglycerides tended to be
greater. There were no significant differences in age, body weight,
HbA1c, blood glucose, and serum cholesterol between the two
groups.
Patients with proteinuria were followed for 2 years. During this
period, patients were treated with irbesartan, in a dose titrated from
75 to 300 mg/day, alone or associated with angiotensin-converting
enzyme inhibitors (ramipril 1.25–5 mg/day) and/or nifedipine
(5–10 mg/day) to achieve the targets of a systolic blood pressure of
135 mm Hg or less, and a diastolic blood pressure of 85 mm Hg or
less. Baseline blood pressures were taken as the average of seated
blood pressures during two visits before the kidney biopsy.
Proteinuria was measured by the immunoturbidimetric method.
The GFR was estimated according to the abbreviated MDRD
equation.42 HbA1c was measured by high-pressure liquid chromato-
graphy. Blood glucose, total cholesterol, LDL-cholesterol, trigly-
ceride, and HDL-cholesterol were determined by the routine clinical
chemistry laboratory.
Reagents
Monoclonal antibody (Ab) F7-26 ssDNA was obtained from Bender
Medsystems (Vienna, Austria), monoclonal Ab to proliferating cell
nuclear antigen from Novocastra Laboratories Ltd (Newcastle upon
Tyne, UK), polyclonal Ab to Fas and FasL from Upstate Bio-
technology (Lake Placid, NY, USA), polyclonal Ab anti-phospho-
p38 MAPK (T180/Y182) from R&D Systems (Minneapolis, MN,
USA), the biotin-streptavidin-amplified detection system from
Vector Laboratories Inc. (Burlingame, CA USA), Eukitt from
Kindler GmbH & Co (Freiburg, Germany), and terminal deox-
ynucleotidyl transferase buffer, terminal deoxynucleotidyl transfer-
ase, and biotinylated dUTP from Boehringer (Mannheim,
Germany). Other reagents, if not indicated, were obtained by Sigma
Chemical Co. (St Louise, MO, USA).
Apoptosis assay in kidney biopsy samples
Paraffin sections (5 mm) of 2% paraformaldeyde-fixed renal biopsies
were deparaffined, hydrated, and treated with 3% H2O2 in
methanol. Samples were analyzed for phospho-p38 detection after
Table 5 | Clinical characteristics of patients with type II
diabetic nephropathy (n=24)
Diabetic nephropathy Group 1 Group 2
Number of patients 12 12
Age (years) 5772 6272
Gender (M/F) 8/4 8/4
Duration of disease (months) 141734 150736
Systolic blood pressure (mm Hg) 14773 16376a
Diastolic blood pressure (mm Hg) 8871 8474
Serum creatinine (mg/dl) 0.9670.1 2.3070.3b
Estimated GFR (ml/min per 1.73 m2) 8178 3474b
Urinary proteins (g/day) 0.8470.21 5.071.3a
Serum albumin (g/dl) 3.970.1 3.470.2
Blood glucose (mg/dl) 143714 135713
HbA1c (%) 7.270.44 8.470.7
Total cholesterol (mg/dl) 227711 212715
LDL-cholesterol (mg/dl) 135712 13577
HDL-cholesterol (mg/dl) 5576 5276
Triglycerides (mg/dl) 185722 240744
F, female; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; M, male.
Data are mean7s.e.m.
Significance of difference vs group 1.
aPo0.05.
bPo0.01.
Table 6 | Structural changes in patients with type II diabetic
nephropathy
Group 1
(proteinuria)
Group 2 (moderate/advanced
CKD)
Number of glomeruli 8 (6–16) 11 (5–20)
Glomerular sclerosis 0 (0–2) 2 (0–3)
Glomerular hyalinosis 1 (0–1) 1 (0–3)
Mesangial proliferation 0 (0–2) 1 (0–2)
Glomerular ischemic
lesions
0 (0–2) 0 (0–3)
Microaneurisms 0 (0–2) 0 (0–3)
Interstitial fibrosis 0 (0–3) 3 (1–3)
Interstitial flogosis 0 (0–3) 1 (0–3)
Tubular atrophy 0 (0–3) 3 (1–3)
Atherosclerosis 1 (0–2) 2 (2–3)
Arteriolosclerosis 0 (0–2) 2 (0–3)
Arteriolar hyalinosis 2 (1–2) 2 (0–3)
Global score 5 (2–11) 20 (13–27)
CKD, chronic kidney disease.
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microwave oven treatment in 0.1 M sodium citrate. All specimens for
apoptosis detection were analyzed by the same pathologist
(Dr Verzola). Features of apoptotic cells stained by the two
techniques included chromatin condensation, nuclear fragmenta-
tion, and cellular shrinking. At least five (range 5–10) glomeruli
from each biopsy were systematically serially sectioned. These
sections were used to estimate cell number by light microscopy.
Endothelial cells were identified as being within the capillary lumen
and integral to the filtration surface or mesangiocapillary surface,
mesangial cells were defined as those completely within the
mesangium, and podocytes were defined as being in urinary space
within the glomerular tuft. Proximal and distal tubular cells were
identified primarily by morphologic criteria, including the presence
of a brush border, cell size, and nuclearcytoplasmic ratio.
Immunohistochemical detection of ssDNA, TUNEL,
Fas, FasL, and phospho-p38 MAPK
After incubation in ice-cold 0.1 N HCl for 15 min and in 0.2% Triton
X-100 for 5 min, slides were boiled in 5 mM MgCl2 solution for
5 min and then transferred in ice-cold water for 10 min. Sections
were exposed to 10 mg/ml monoclonal Ab F7-26 ssDNA for 30 min,
followed by incubation with the secondary Ab (biotynilated
immunoglobulins 1:100 in phosphate-buffered saline for 30 min).
The biotin-extravidin peroxidase method and light microscopy
examination were performed as described previously.8
For the TUNEL assay, sections were incubated with proteinase K
(3mg/ml) for 20 min at 371C. Then, the sections were immersed in
terminal deoxynucleotidyl transferase buffer containing terminal
deoxynucleotidyl transferase (100 U/ml), and biotynilated dUTP
(0.5 mg/ml) at 371C for 1 h. The reaction was terminated by
transferring slides to a working-strength stop/wash buffer (30 mM
sodium citrate, 300 mM sodium chloride) for 15 min. Afterward,
immunostaining was completed as for the ssDNA assay. For both
techniques (anti-ssDNA and TUNEL), the degree of apoptosis was
estimated by counting the number of ssDNA-positive cells per 100
cells examined in average of five high-power fields (original
magnification  1000) in each section.
Fas and FasL were detected by incubating the sections with
specific Ab (both 1:40 in phosphate-buffered saline) for 30 min. For
detection of phospho-p38 MAPK, the sections were incubated with
the Ab (5 mg/ml) overnight at 41C. The successive steps were
performed as described previously. For immunofluorescence,
immunostaining was completed adding extravidin fluorescein
isothiocyanate (1:250 in phosphate-buffered saline) for 15 min.
Slides were then analyzed with a fluorescence microscope.
Proliferation assay in kidney biopsy samples
The sections were incubated with a monoclonal Ab to proliferating
cell nuclear antigen (1:500 dilution) and the detection was
accomplished by immunoperoxidase staining. Slides were examined
in a blinded manner, and proliferation was quantified by counting
the number of proliferating cell nuclear antigen-positive cells per
100 cells (proliferative index) counted at high-power field (original
magnification  1000) in each section.
Image analysis
Image analysis was performed by Leica Q500 MC Image Analysis
System (Leica, Cambridge, UK). For each sample, all glomeruli and
all tubules were analyzed (original magnification  1000) and the
optical density of the signals was quantitated by a PC as reported
previously.8
Statistical analysis
Data are presented as means7s.e.m. or, when skewed, median
(range). The Statview statistical package (Cary, NC, USA) was used
for the analysis. Means were compared for statistically significant
differences by t-test and analysis of variance when two or more than
two groups, respectively, were involved. Relationships between
parameters were analyzed using simple regression analysis or
Spearman test, as required. Stepwise multiple regression analysis
was performed to assess whether glomerular and tubular apoptosis
were independent predictors of loss of renal function. Potential
independent predictor variables included proteinuria at the time of
renal biopsy, histologic global score, estimated GFR as well the
number of apoptotic tubular, and glomerular cells. A two-tailed
Po0.05 was considered statistically significant.
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